WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) announced Wednesday that
it has entered into a new clinical study collaboration with Cellular Biomedicine
Group Inc. (CBMG).

The study will evaluate Nektar's NKTR-255, a novel interleukin-15 (IL-15)
receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating
lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC)
patients that are relapsed or refractory to anti-PD-1 therapy.

Preclinical and early clinical data suggest that IL-15 can improve proliferation
and persistence of cellular therapies including TIL, TCR, and CAR-T therapies to
increase specific anti-tumor activity.

Under the new collaboration, CBMG will add NKTR-255 to its ongoing
CBMG-sponsored Phase 1 clinical trial evaluating C-TIL051 in NSCLC patients who
have relapsed on or were refractory to anti-PD-1 therapy.

The study is expected to enroll a total of 20 patients. Nektar will contribute
NKTR-255 supply for the study. Nektar and CBMG will each maintain existing
global rights to their respective investigational medicines.

For More Such Health News, visit rttnews.com



Copyright(c) 2023 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX